Literature DB >> 16875747

Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I.

Tomas Raviña, Paula Raviña, Javier Gutierrez.   

Abstract

The acquired Long QT Syndrome (aLQTS) is attributed to subtle defects in genes encoding potassium currents (Ik) that may become clinically significant when associated with other factors that impair ventricular repolarization, such as female gender, bradycardia, hypokalemia or the administration of ion channel blocking drugs. We describe full exposure of an aLQTS in a elderly female patient on long-term Risperidone treatment just when bradycardia due to complete AV block developed. We postulate that the aLQTS induced is the result of a combined block of the rapid (I(Kr))and delayed (I(Ks)) components of the Ik current. The electrocardiographic manifestation of (likely) phase 2 early afterdepolarizations and a critical transmural dispersion of repolarization (TDR), both required for the initiation and maintenance of the polymorphic ventricular tachycardia associated with the syndrome (Torsades de Pointes), are as well shown. Risperidone should be used with caution in female patients prone to bradycardia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875747     DOI: 10.1016/j.ijcard.2006.04.084

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

2.  Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.

Authors:  Gerrit Frommeyer; Henning von der Ahe; Benedict Brücher; Dirk G Dechering; Philipp S Lange; Florian Reinke; Kristina Wasmer; Julia Köbe; Christian Pott; Gerold Mönnig; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-12       Impact factor: 3.000

3.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

Review 4.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

Review 5.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 6.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

7.  Sudden death of cardiac origin and psychotropic drugs.

Authors:  Quadiri Timour; Dominique Frassati; Jacques Descotes; Philippe Chevalier; Georges Christé; Mohamed Chahine
Journal:  Front Pharmacol       Date:  2012-05-10       Impact factor: 5.810

8.  Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes.

Authors:  Lei Ruan; Xiaoqing Quan; Liandong Li; Rong Bai; Mingke Ni; Rende Xu; Cuntai Zhang
Journal:  Exp Ther Med       Date:  2014-03-04       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.